1. Home
  2. HIT vs MGNX Comparison

HIT vs MGNX Comparison

Compare HIT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HIT
  • MGNX
  • Stock Information
  • Founded
  • HIT 1964
  • MGNX 2000
  • Country
  • HIT United States
  • MGNX United States
  • Employees
  • HIT N/A
  • MGNX N/A
  • Industry
  • HIT Specialty Insurers
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HIT Finance
  • MGNX Health Care
  • Exchange
  • HIT Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • HIT 122.9M
  • MGNX 99.7M
  • IPO Year
  • HIT 2024
  • MGNX 2013
  • Fundamental
  • Price
  • HIT $2.76
  • MGNX $1.77
  • Analyst Decision
  • HIT Strong Buy
  • MGNX Hold
  • Analyst Count
  • HIT 1
  • MGNX 5
  • Target Price
  • HIT $2.50
  • MGNX $3.25
  • AVG Volume (30 Days)
  • HIT 942.3K
  • MGNX 548.1K
  • Earning Date
  • HIT 07-21-2025
  • MGNX 08-14-2025
  • Dividend Yield
  • HIT N/A
  • MGNX N/A
  • EPS Growth
  • HIT N/A
  • MGNX N/A
  • EPS
  • HIT 0.02
  • MGNX N/A
  • Revenue
  • HIT $26,692,318.00
  • MGNX $165,495,000.00
  • Revenue This Year
  • HIT $70.02
  • MGNX N/A
  • Revenue Next Year
  • HIT $63.39
  • MGNX N/A
  • P/E Ratio
  • HIT $132.57
  • MGNX N/A
  • Revenue Growth
  • HIT 29.68
  • MGNX 303.47
  • 52 Week Low
  • HIT $0.51
  • MGNX $0.99
  • 52 Week High
  • HIT $7.59
  • MGNX $5.10
  • Technical
  • Relative Strength Index (RSI)
  • HIT 55.13
  • MGNX 58.62
  • Support Level
  • HIT $2.72
  • MGNX $1.69
  • Resistance Level
  • HIT $3.60
  • MGNX $1.87
  • Average True Range (ATR)
  • HIT 0.41
  • MGNX 0.12
  • MACD
  • HIT -0.11
  • MGNX 0.02
  • Stochastic Oscillator
  • HIT 14.48
  • MGNX 77.27

About HIT Health In Tech Inc. Class A Common Stock

Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: